Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | PYGB | P11216 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20610479 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL7109528 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL27170351 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL2493227 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL2489683 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL28106543 | 1.00 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13955988 | 0.85 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL19975699 | 0.85 | LGALS1 (0.33) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL16837353 | 0.85 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13955989 | 0.85 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082279-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING SCARS | L'OREAL (FR) | 2024-03-14 | — | — | US | claimed |
| US-20240082279-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING SCARS | L'OREAL (FR) | 2024-03-14 | — | — | US | disclosed |
| WO-2024049923-A1 | COMPOSITIONS AND METHODS FOR SKIN | L'OREAL (FR) | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082279-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING SCARS | CUTA, MMP8, MMP1 | LGALS1 36/4885LGALS3 16/4885LGALS9 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.